Rank the aquisitions Pharmion, Gloucester, Abraxis......

Discussion in 'Celgene' started by Anonymous, Mar 23, 2011 at 10:59 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    1,2,3 its that simple.
     

  2. Anonymous

    Anonymous Guest

    Can we use fractions or negative numbers?
     
  3. Anonymous

    Anonymous Guest

    What a joke. Paid $2.9 billion for abraxane when there is generic paclitaxel and docetaxel.
     
  4. Anonymous

    Anonymous Guest

    Can't wait till it is Celgene's turn to be the one bought. I hope you are treated exactly as you treated others.
     
  5. Anonymous

    Anonymous Guest

    They all kind of make Wall Street scratch their head and go hmmmmmm?? What were they thinking???

    Pharmion- Vidaza going generic
    Gloucester- Istodax uptake is so slow the sales numbers are not in quarterly earnings
    Abraxis- Selling against two generic taxanes?? Even with the latest price increase for Abraxane numbers will trend down.
     
  6. Anonymous

    Anonymous Guest

    At Celgene, Bigger Isn’t Better: Why Acquisitions Are Ruining a Once Great Company.

    This is from a Teva article today, but it applies to Celgene. The once great company Celgene now has more products, but still only one growth driver, Revlimid.